Scholar Rock Announces FDA Approval of ISEMBYLD for SMA

What Happened Scholar Rock Holding Corp. announced on September 11, 2026 (filed on Form 8-K on September 14, 2026) that the U.S. Food and Drug Administration approved ISEMBYLD™ (apitegromab‑mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)‑targeted treatment. The company issued a press release and provided presentation materials, and will host a webcast and conference call on September 14, 2026 at 8:00 a.m. Eastern Time to discuss the approval.

Key Details

• Approval announced: September 11, 2026; Form 8‑K filed September 14, 2026 (Items 7.01 and 8.01).
• Product: ISEMBYLD™ (apitegromab‑mstn) for SMA in adults and children aged 2+ who are receiving SMN2‑targeted therapy.
• Investor materials: Press release and presentation furnished as exhibits; webcast/conference call scheduled for September 14, 2026 at 8:00 a.m. ET.

Why It Matters FDA approval is a regulatory milestone that allows Scholar Rock to seek commercialization and promote ISEMBYLD in the United States for the specified SMA population. For investors, this is a material corporate development that may affect the company’s product pipeline outlook and future commercial activities; the company has provided materials and a webcast to discuss next steps.